Search

Edwards Lifesciences Corp

Закрыт

СекторЗдравоохранение

85.64 2.51

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

82.71

Макс.

85.47

Ключевые показатели

By Trading Economics

Доход

290M

381M

Продажи

92M

1.7B

P/E

Средняя по отрасли

49.429

64.641

Прибыль на акцию

0.78

Рентабельность продаж

23.092

Сотрудники

16,000

EBITDA

20M

520M

Рекомендации

By TipRanks

Рекомендации

Активная покупка

Прогноз на 12 месяцев

+22.94% upside

Дивиденды

By Acuity

Следующий отчет о доходах

29 окт. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-1.1B

48B

Предыдущая цена открытия

83.13

Предыдущая цена закрытия

85.64

Новостные настроения

By Acuity

55%

45%

253 / 340 Рейтинг в Healthcare

Edwards Lifesciences Corp График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

28 июл. 2026 г., 18:46 UTC

News

UBS analyst Danielle Antalffy initiated coverage on Edwards Lifesciences with a Buy rating and $110 price target, boosting shares modestly higher today.

27 июл. 2026 г., 19:41 UTC

Social Media
News

Edwards Lifesciences shares rise as TAVR revenue hits $35 million, driven by a 10.5% increase in U.S. sales, surpassing expectations.

24 июл. 2026 г., 18:41 UTC

News

Edwards Lifesciences Corp is trading lower today despite positive analyst ratings. The stock pulled back from an earlier session high and has declined since Thursday's close.

23 июл. 2026 г., 23:41 UTC

News
Event

Edwards Lifesciences reported Q2 sales of $1.74 billion, exceeding expectations. Shares are gaining in after-market hours following the results and raised guidance.

22 июл. 2026 г., 18:46 UTC

Edwards Lifesciences shares are trading higher during Wednesday's session, showing slight gains despite recent declines in the broader market.

21 июл. 2026 г., 21:02 UTC

Edwards Lifesciences Corp shares are lower in after-market hours, continuing a trend of three consecutive sessions below the 20-day moving average.

20 июл. 2026 г., 19:56 UTC

News

Edwards Lifesciences shares are lower as regulatory challenges arise from a $12 million FTC penalty and new restrictions on valve replacement agreements.

Сравнение c конкурентами

Изменение цены

Edwards Lifesciences Corp Прогноз

Целевая цена

By TipRanks

22.94% рост

Прогноз на 12 месяцев

Средняя 102.88 USD  22.94%

Максимум 110 USD

Минимум 85 USD

Основано на мнении 19 аналитиков Wall Street, спрогнозировавших целевые цены для Edwards Lifesciences Corp на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Активная покупка

19 ratings

16

Покупка

3

Удержание

0

Продажа

Настроения

By Acuity

253 / 340Рейтинг в Здравоохранение

Новостные настроения

Свидетельства нисходящего тренда

Волатильность

Ниже среднего

Объем новостей (RCV)

Выше среднего

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Edwards Lifesciences Corp

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names. The company also provides surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; INSPIRIS RESILLA aortic valve, which offers RESILIA tissue and VFit technology; KONECT RESILIA, a pre-assembled tissue valves conduit for complex combined procedures; and MITRIS RESILIA valve. In addition, it offers critical care solutions, including hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings under the FloTrac, Acumen IQ sensors, ClearSight, Acumen IQ cuffs, and ForeSight names; HemoSphere, a monitoring platform that displays physiological information; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
help-icon Live chat